I have no idea, but given he hasn’t walked out the door yet and...

I have no idea, but given he hasn’t walked out the door yet and he is now 4 months into the role, I take it as a small positive.

Ave, no one knows how this plays out. Donna’s subtle enthusiasm during webinars when reporting on 008 outcomes rings in my ears. Our data is making her happy and that’s enough for me to sleep at night for now. Disclaimer, I rate Doc Donna.

Other posters have pointed out the extreme increase in share price pre rev biotechs can attain when the certainty is assured. I suspect we are at the moment of maximum uncertainty (dose/trial design) and our cash balance is not helpful (in fact worrying) and I suspect this alone is weighing on sentiment as these last hurdles aren’t usually cheap (phase 3 trial completion).

There are many other frustrations we are all going through but none are important at this point on the shot clock. Are we in the 4th quarter in the dying seconds, buzzer about the ring on the wrong side of the FDA? Or at the end of the 3rd quarter with a 4th quarter to come. I don’t know.